A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder

Trial Profile

A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Duloxetine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 25 Oct 2016 Results of a post-hoc analysis assessing the effect of vortioxetine on cognitive functioning and depressive symptoms from 5 studies, published in the Journal of Clinical Psychiatry.
    • 01 Sep 2015 Results of meta analysis of pooled data from 9 trials presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
    • 21 Jun 2012 Additional trial location (Finland) identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top